Apprentice Raises $100 Million To Adapt Pharma Supply Chains To The Omicron Variant
01/19/22, 8:00 AM
Money raised
$100 million
Apprentice, the company helping pharma manufacturers get medicine to patients faster, announced today that it raised $100 million in Series C funding led by new investor Alkeon Capital Management, with repeat participation from Silverton Partners, Insight Partners, Pacific Western Bank, and new investment by Colorcon Ventures. The company will use the capital to help pharma manufacturers harden their supply chains to keep making patient-critical drugs and adapt vaccines to meet the evolving strains of COVID-19.
Company Info
Additional Info
Apprentice's disruptive technology helps pharma manufacturers get medicine to patients faster by providing one platform to turn molecules into medicine. The company's intelligent cloud platform integrates augmented reality, voice recognition, and artificial intelligence into wearable, mobile, and desktop devices to offer a virtual collaboration application and a robust manufacturing and lab execution system that reduce human error and inefficiency in the drug production process. Learn how 15 of the top 20 US Pharma companies use Apprentice to accelerate high-quality production of drugs for diseases of all types, from COVID to cancer, at www.apprentice.io